{"id":938668,"date":"2026-02-20T08:23:20","date_gmt":"2026-02-20T13:23:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/"},"modified":"2026-02-20T08:23:20","modified_gmt":"2026-02-20T13:23:20","slug":"pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/","title":{"rendered":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT \/ 4:30 p.m. ET.<\/p>\n<p align=\"justify\">A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DxX711IX_797B7kL9u2OmZif2cf_14GUkeV2_XTUccRmrePoJ9l1HexwQF031RHIEgBLvQBiJ_PfZ9gAy5orcQ7T_uS9JPMIZp9608NWn4AyC9UHKHfivJKgUwU69aty\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.pulmonx.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Pulmonx Corporation<\/strong><br \/>\n        <br \/>Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx\u2019s Zephyr<sup>\u00ae<\/sup> Endobronchial Valve, Chartis<sup>\u00ae<\/sup> Pulmonary Assessment System, LungTraX\u2122\u00a0Platform, and StratX<sup>\u00ae<\/sup> Lung Analysis Reports are designed to assess and treat patients with severe emphysema\/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a \u201cbreakthrough device.\u201d The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qKI_m0CGvaR5ohz658s6EwISDLv0FkznsMggprUC2J1XRQVsbdC3Zlobl1kn-i3cQqb9BaWcKZK0k10GJ3-8Vj1k9OgVBGOorunoDKbbyihXre35CET46ROdj8aijv62Dmg4-jslFf5p4fs9-gRZsEU27NgwFW-HNF5fKZu3QOEEl-BFyrim_nza2dU6BdBfbUuVEcR3z-rkx4Pzyd3Ylsun0wGPW1z8EAdt48S53F0=\" rel=\"nofollow\" target=\"_blank\">www.Pulmonx.com<\/a>.<\/p>\n<p align=\"justify\">Pulmonx<sup>\u00ae<\/sup>, AeriSeal<sup>\u00ae<\/sup>, Chartis<sup>\u00ae<\/sup>, StratX<sup>\u00ae<\/sup>, and Zephyr<sup>\u00ae<\/sup> are registered trademarks and LungTraX\u2122\u00a0is a trademark of Pulmonx Corporation.<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong><br \/>\n        <br \/>Brian Johnston<br \/>Laine Morgan<br \/>Gilmartin Group<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JFylgPO_L8H_M4dVmP4ti-yUoLWvfp4gFwaMQX5N-6B4wmY6-dzil-kqoDUH0-vQou-SQ1OZQ_PeRLgEAPVL0eUZm871z_jeNDrgNqqaFKk=\" rel=\"nofollow\" target=\"_blank\">investors@pulmonx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjM5MzUyMjEtYmZkOS00YjA3LTkyMjMtOTI1Nzg2ZTA5ODE3LTEyMDYxNDItMjAyNi0wMi0yMC1lbg==\/tiny\/Pulmonx-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT \/ 4:30 p.m. ET. A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-938668","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT \/ 4:30 p.m. ET. A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment &hellip; Continue reading &quot;Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T13:23:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026\",\"datePublished\":\"2026-02-20T13:23:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/\"},\"wordCount\":253,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/\",\"name\":\"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=\",\"datePublished\":\"2026-02-20T13:23:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT \/ 4:30 p.m. ET. A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment &hellip; Continue reading \"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-20T13:23:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026","datePublished":"2026-02-20T13:23:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/"},"wordCount":253,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/","name":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=","datePublished":"2026-02-20T13:23:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEzNSM3NDM1ODA5IzIxOTQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=938668"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938668\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=938668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=938668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=938668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}